We have previously hypothesized that hepatic blood flow may have a more pronounced impact on systemic midazolam clearance than CYP3A4 activity in patients with obesity due to higher liver blood flow in this patient population compared with normal-weight individuals [20]. This evidence concerns the gene CYP3A4 and obesity disorder.